Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02112838 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

IGA Nephropathy

Interventions

DRUG: Fostamatinib 150 mg
DRUG: Fostamatinib 100 mg
DRUG: Placebo

Sponsor

Rigel Pharmaceuticals